Prognostic Significance of Circulating Immune-Inflammatory Biomarkers IL-6 and Systemic Immune-Inflammation Index in Hepatocellular Carcinoma Treated With Immune Checkpoint Inhibitors: A Meta-Analysis
Circulating Immune-Inflammatory Biomarkers in HCC
Abstract
Background: Hepatocellular carcinoma (HCC) is characterized by a chronic inflammatory and immunologically dysregulated microenvironment. Circulating immune-inflammatory biomarkers reflect systemic biochemical and immune alterations and may provide laboratory-accessible indicators for prognosis assessment. However, the prognostic value of interleukin-6 (IL-6) and the systemic immune-inflammation index (SII) in HCC patients receiving immune checkpoint inhibitors (ICIs) remains incompletely defined.
Methods: A comprehensive literature search was conducted across PubMed, Embase, Web of Science, the Cochrane Library, CNKI, and Wanfang Data to identify cohort studies evaluating circulating IL-6 and/or SII in HCC patients treated with ICIs. Hazard ratios (HRs) with 95% confidence intervals (CIs) for progression-free survival (PFS) and overall survival (OS) were pooled using fixed- or random-effects models. Subgroup and sensitivity analyses were performed to explore sources of heterogeneity.
Results: Twelve studies involving 1,508 patients were included. Elevated circulating IL-6 levels were significantly associated with poorer PFS (HR = 1.91, 95% CI 1.40–2.60) and OS (HR = 2.13, 95% CI 1.52–2.97), with robust results across sensitivity analyses. In contrast, the prognostic value of SII was context-dependent. Higher SII was significantly associated with shorter PFS in non-100% hepatitis B virus–related HCC populations and with poorer OS in patients receiving combined local treatment, while no significant associations were observed in other subgroups.
Conclusions: Circulating IL-6 serves as a stable immune-biochemical prognostic biomarker in HCC patients treated with ICIs, whereas the prognostic relevance of SII is modulated by disease etiology and treatment modality. These findings provide laboratory-relevant biochemical evidence supporting the integration of circulating immune-inflammatory markers into prognostic evaluation frameworks for HCC.
References
2. Alawyia B, Constantinou C. Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future Prospects. Curr Treat Option On 2023; 24(7): 711-24.
3. Chen Y, Dai S, Cheng C, Chen L. Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives. J Hematol Oncol 2024; 17(1): 130.
4. Yu L, Ling Y, Wang H. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. Npj Precis Oncol 2018; 2(1): 6.
5. Ren X, Zhou Y, Luo Y, Wang C, Pan A, Ju Y, et al. IL-6 Promotes Hepatocellular Carcinoma Invasion by Releasing Exosomal miR-133a-3p. Gastroent Res Pract 2022; 2022: 4589163.
6. Tchilikidi KY. Actuality and underlying mechanisms of systemic immune-inflammation index and geriatric nutritional risk index prognostic value in hepatocellular carcinoma. World J Gastro Surg 2024; 16(2): 260-5.
7. Zhang L, Feng J, Kuang T, Chai D, Qiu Z, Deng W, et al. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies. Int Immunopharmacol 2023; 118: 110019.
8. Liu C, Zhao H, Zhang R, Guo Z, Wang P, Qu Z. Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors. Oncol Lett 2023; 26(4): 437.
9. Jia G, Qiu L, Zheng H, Qin B, Sun Z, Shao Y, et al. Nomogram for predicting survival in patients with advanced hepatocellular carcinoma treated with PD-1 inhibitors: incorporating pre-treatment and post-treatment clinical parameters. Bmc Cancer 2023; 23(1): 556.
10. Du J, Huang Z, Zhang E. Nomograms confirm serum IL-6 and CRP as predictors of immune checkpoint inhibitor efficacy in unresectable hepatocellular carcinoma. Front Immunol 2024; 15: 1329634.
11. Huang R, Zheng Y, Zou W, Liu C, Liu J, Yue J. Blood Biomarkers Predict Survival Outcomes in Patients with Hepatitis B Virus-Induced Hepatocellular Carcinoma Treated with PD-1 Inhibitors. J Immunol Res 2022; 2022: 3781109.
12. Miura R, Ono A, Nakahara H, Shirane Y, Yamaoka K, Fujii Y, et al. Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma. J Gastroenterol 2025; 60(3): 328-39.
13. Suzuki T, Matsuura K, Suzuki Y, Okumura F, Nagura Y, Sobue S, et al. Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis. J Gastroen Hepatol 2024; 39(10): 2158-68.
14. Yao Y, Zhang M, Liu D, Liu X, Li Q, Wang X. Changes in systemic immune-inflammation index (SII) predict the prognosis of patients with hepatitis B-related hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors. Clinical & Translational Oncology: Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2025; 27(3): 1155-65.
15. Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y, et al. Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy. Cancers 2022; 14(4): 883.
16. Kocheise L, Kempski J, Tang Y, Balcar L, Berger V, Tomczak M, et al. Serum IL-6 is a prognostic biomarker for advanced hepatocellular carcinoma treated with atezolizumab and bevacizumab. Ann Hepatol 2025; 31(1): 102138.
17. Zhang T, Liu RR, Zhao CH, Xu JM. Dynamic changes of peripheral blood inflammatory markers for predicting effectiveness of immunotherapy combined with anti-angiogenesis therapy for advanced hepatocellular carcinoma: Analysis of RESCUE follow-up data. Academic Journal of Chinese PLA Medical School 2024; 45(04): 384-390+410.
18. Zhuang MT, Cui JJ, Zhou F, Yao J X, Shi Y H, Fei SJ. Prognostic value of PNI and SII in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization combined with camrelizumab and tyrosine kinase inhibitors. Journal of Xuzhou Medical University 2024; 44(10): 725-732.
19. Jiang S, Xu YT, Liu X, Chen WL, Xu XM. Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy. Journal of International Oncology 2023; 50(10): 600-607.
20. Tian B, Yang Y, Yang C, Yan L, Ding Z, Liu H, et al. Systemic immune-inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis. Immunotherapy-UK 2022; 14(18): 1481-96.
21. Xue R, Zhang Q, Cao Q, Kong R, Xiang X, Liu H, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 2022; 612(7938): 141-7.
22. Yang M, Lin S, Liu X, Tang M, Hu C, Wang Z, et al. Association between C-reactive protein-albumin-lymphocyte (CALLY) index and overall survival in patients with colorectal cancer: From the investigation on nutrition status and clinical outcome of common cancers study. Front Immunol 2023; 14: 1131496.
23. Rodriguez-Martinez A, Simon-Saez I, Perales S, Garrido-Navas C, Russo A, de Miguel-Perez D, et al. Exchange of cellular components between platelets and tumor cells: impact on tumor cells behavior. Theranostics 2022; 12(5): 2150-61.
24. Li S, Huang W, Li J, An T, Li H, Hu C, et al. Skeletal muscle index/systemic immune-inflammation index (SMI/SII) ratio predicts prognosis in patients with hepatocellular carcinoma. World J Surg Oncol 2025; 23(1): 178.
25. Zhang W, Liu Y, Yan Z, Yang H, Sun W, Yao Y, et al. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma. J Immunother Cancer 2020; 8(1): e000285.
26. Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, et al. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment. Cancer Res 2018; 78(17): 5011-22.
Copyright (c) 2026 Enze Hu, Yuanfu Qiu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.